Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aquestive Therapeutics Inc (AQST)

Aquestive Therapeutics Inc (AQST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 527,234
  • Shares Outstanding, K 122,045
  • Annual Sales, $ 44,550 K
  • Annual Income, $ -83,780 K
  • EBIT $ -71 M
  • EBITDA $ -60 M
  • 60-Month Beta 1.54
  • Price/Sales 11.67
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 79.15% (-3.21%)
  • Historical Volatility 39.33%
  • IV Percentile 7%
  • IV Rank 3.86%
  • IV High 382.65% on 06/16/25
  • IV Low 66.96% on 04/15/26
  • Expected Move (DTE 26) 0.67 (15.54%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 3,611
  • Volume Avg (30-Day) 1,661
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 57,243
  • Open Int (30-Day) 53,087
  • Expected Range 3.65 to 4.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.14
  • Number of Estimates 5
  • High Estimate $-0.12
  • Low Estimate $-0.21
  • Prior Year $-0.24
  • Growth Rate Est. (year over year) +41.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.77 +14.70%
on 03/24/26
4.40 -1.82%
on 04/17/26
+0.21 (+5.11%)
since 03/17/26
3-Month
2.93 +47.44%
on 01/30/26
4.50 -4.00%
on 03/05/26
+1.01 (+30.51%)
since 01/16/26
52-Week
2.12 +103.77%
on 05/13/25
7.55 -42.78%
on 10/20/25
+1.81 (+72.11%)
since 04/17/25

Most Recent Stories

More News
AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , April 16, 2026 /PRNewswire/ --

AQST : 4.32 (+1.41%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - AQST

NEW YORK , April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such...

AQST : 4.32 (+1.41%)
AQST INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options

AQST : 4.32 (+1.41%)
AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt

Disclosure Under Scrutiny: Were Risk Warnings Adequate for Aquestive's Anaphylm NDA?

AQST : 4.32 (+1.41%)
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: Levi & Korsinsky

Wall Street Reassessment: Analyst Opinion Evolution on AQST

AQST : 4.32 (+1.41%)
AQST Shareholder Alert: May 4, 2026 Lead Plaintiff Deadline in Aquestive Therapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm

NEW YORK , April 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of  Aquestive Therapeutics, Inc. (NASDAQ: AQST).

AQST : 4.32 (+1.41%)
AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , April 11, 2026 /PRNewswire/ --

AQST : 4.32 (+1.41%)
AQST UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options

AQST : 4.32 (+1.41%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - AQST

NEW YORK , April 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such...

AQST : 4.32 (+1.41%)
AQST Shareholder Alert: May 4, 2026 Lead Plaintiff Deadline in Aquestive Therapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm

NEW YORK , April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST).

AQST : 4.32 (+1.41%)

Business Summary

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based...

See More

Key Turning Points

3rd Resistance Point 4.50
2nd Resistance Point 4.45
1st Resistance Point 4.39
Last Price 4.32
1st Support Level 4.27
2nd Support Level 4.22
3rd Support Level 4.15

See More

52-Week High 7.55
Fibonacci 61.8% 5.48
Fibonacci 50% 4.84
Last Price 4.32
Fibonacci 38.2% 4.19
52-Week Low 2.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.